Phase 3 N=105 Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma
Retinoblastoma · Retinal Neoplasm
Primary: Stratum B Response to Window Therapy — 24; 2; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=14 Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma
Unilateral Retinoblastoma
Primary: Number of Patients Experiencing Feasibility Failure — 4 participants
Phase 4 N=26 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma
Retinoblastoma
Primary: Event Free Survival Rate — 7; 4 participants — p=0.034
Phase 3 N=30 Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma
Intraocular Retinoblastoma
Primary: Group D Eyes - Treatment Failure Within One Year — 0.52 Probability of treatment failure
Phase 3 N=60 Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
Extraocular Retinoblastoma
Primary: Event-free Survival (EFS) — 88; 83; 28 Probability
Phase 3 N=28 Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma
Intraocular Retinoblastoma
Primary: Event-free Survival — 0.65 Proportion of participants
Phase 3 N=331 Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma
Intraocular Retinoblastoma
Primary: Event-free Survival (EFS) — 0.9394; 0.9953 Estimated Probability
Phase 4 N=52 Contralateral ReSTOR / Monofocal or Phakic Eye
Cataracts
Primary: Visual Acuity — -0.04; -0.01; 0.14; 0.18 LogMar
Phase 4 N=35 VISmodegib for ORbital and Periocular Basal Cell Carcinoma
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants
N/A N=1,007 Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer
Breast Cancer · Contralateral Breast Cancer
Primary: MRI Diagnostic Yield of Cancers in the Contralateral Breast — 30; 114; 3; 822 Participants
N/A N=40 Symmetric vs Asymmetric BLR Recession in Management of Basic IXT With Ocular Dominance
Intermittent Exotropia
Primary: Ocular Alignment at Distant Fixation — 5.8; 1.1 prism diopter
Phase 2 N=23 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm · Recurrent Childhood Ependymoma · Recurrent Ewing Sarcoma
Primary: Objective Response Rate — 0 percentage of participants
Phase 3 N=225 RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity
Retinopathy of Prematurity
Primary: Percentage of Participants With Absence of Active ROP and Absence of Unfavorable Structural Outcomes in Both Eyes at Week 24 — 80.0; 75.0; 66.2 Percentage of…
Phase 2 N=3 A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
Von Hippel-Lindau Syndrome
Primary: Tabulation of Adverse Events — 13 adverse events
Phase 1 N=120 Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity
Retinopathy of Prematurity
Primary: Number of Participants With Successful Treatment of ROP — 11; 14; 21; 9 Participants
Phase 2 N=20 Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity: A Randomized and Prospective Study
Retinopathy of Prematurity
Primary: Regression of Retinopathy of Prematurity (ROP) in Premature Infants by Propranolol Therapy — 4; 8 cases
Phase 1 N=5 Effect of Ranibizumab on Malignant Conjunctival Neoplasia
Conjunctival Neoplasms
Primary: Number of Patients Assessed for Safety and Tolerability — 5 participants
Phase 2 N=121 IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Retinopathy of Prematurity (ROP)
Primary: Severity of Retinopathy of Prematurity (ROP) as Compared to the Severity of ROP in an Untreated Control Population — 14; 24; 4; 4 participants — p=0.0642
Phase 2 N=5 RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration
Age Related Macular Degeneration
Primary: Macular Edema — 416 Microns
Phase 2 N=296 Bevacizumab Against Recurrent Retinal Detachment
Retinal Detachment · Proliferative Vitreoretinopathy
Primary: Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery — 92; 169 Participants
Phase 2 N=12 Antineoplaston Therapy in Treating Children With Visual Pathway Glioma
Visual Pathway Glioma
Primary: Number of Participants With Objective Response — 2; 2; 3; 1 Participants
Phase 2 N=12 REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
Macular Edema · Branch Retinal Vein Occlusion
Primary: Visual Acuity — 16.8; 14.5; 19.1; 15.3 letters on ETDRS Visual Acuity Chart
Phase 2 N=17 Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
Melanoma
Primary: Clinical Responses in Patients With Metastatic Ocular Melanoma — 0; 0; 9; 7 Participants
Phase 2 N=9 RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration
Age-related Macular Degeneration
Primary: Ocular Safety as Assessed Using Biomicroscopy to Investigate Ocular Tolerability — 0; 0; 1 Participants
Phase 2 N=64 Therapy for Children With Advanced Stage Neuroblastoma
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
Phase 2 N=44 Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
Retinitis Pigmentosa · Usher Syndrome Type 2 · Usher Syndrome Type 3
Primary: Mean Change in Cone Spacing in Arcminutes (Z Score) of 2 Baseline Values Were Compared With Measurements Obtained at Post-op Month 36 — 1.13; 0.85 Difference in change…
Phase 2 N=34 Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
Oligodendroglioma · Oligoastrocytoma
Primary: Progression-free Survival (PFS) at Six Months (PFS6m) — 21 Percentage of participants
Phase 2 N=34 Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Uveal Melanoma
Primary: Relapse Free Survival (RFS) Rate at 32 Months — 50 Probability
Phase 2 N=38 Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Ciliary Body and Choroid Melanoma, Medium/Large Size · Ciliary Body and Choroid Melanoma, Small Size · Iris Melanoma
Primary: Number of Patients With Disease-free Survival (DFS) — 8 Participants
Phase 2 N=18 Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)
RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy
Primary: Change in the Percentage of White Matter Hyperintensity (WMH) Lesion Volume on FLAIR MRI in RVCL Patients — 31.3 Percent (%)